PhI data puts Novartis on track to deliver H7N9 vaccine

Novartis ($NVS) has posted positive Phase I data for its H7N9 vaccine, which is now in large-scale production. The trial found two doses of the adjuvanted cell culture vaccine immunologically protected 85% of participants. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.